AstraZeneca has entered into an agreement to acquire CinCor Pharma, a clinical-stage biopharmaceutical company, focused on developing treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. As part of the deal, the company will acquire CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!